WithdrawnPhase 2/3

Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus

Stopped: Low eligibility of patients, no successful recruitment

United States0Started 2017-05-04

Plain-language summary

The study will investigate the efficacy of the N-methyl-D-aspartate receptor antagonist ketamine as a first line agent in refractory status epilepticus versus traditional general anesthetic agents used for burst suppression that target the gamma-aminobutyric acid adrenergic receptors.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients more than 18 years of age with a diagnosis of status epilepticus * Considered for burst suppression therapy after failing 2 or 3 anti-epileptic medications Exclusion Criteria: * Post anoxic status epilepticus * Pregnant women, as confirmed by urine, or blood human chorionic gonadotropin, ultrasound or physical exam * Prisoners * Age less than 18 years * Allergy or sensitivity to the drug in question

What they're measuring

Time taken for burst suppression

Timeframe: Baseline to 1 hr

Time taken for termination of seizures

Timeframe: Baseline to 24 hrs

Trial details

NCT IDNCT03115489

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12-31

View on ClinicalTrials.gov More Refractory Epilepsy trials